IMP321: Ph I TACTI-mel ongoing

A DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE